989 related articles for article (PubMed ID: 32226290)
21. Management of epigenomic networks entailed in coronavirus infections and COVID-19.
El Baba R; Herbein G
Clin Epigenetics; 2020 Aug; 12(1):118. PubMed ID: 32758273
[TBL] [Abstract][Full Text] [Related]
22. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
23. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
Krishna G; Pillai VS; Veettil MV
Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
[TBL] [Abstract][Full Text] [Related]
24. A global treatments for coronaviruses including COVID-19.
Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
[TBL] [Abstract][Full Text] [Related]
25. Coronavirus Disease 2019-COVID-19.
Dhama K; Khan S; Tiwari R; Sircar S; Bhat S; Malik YS; Singh KP; Chaicumpa W; Bonilla-Aldana DK; Rodriguez-Morales AJ
Clin Microbiol Rev; 2020 Sep; 33(4):. PubMed ID: 32580969
[TBL] [Abstract][Full Text] [Related]
26. The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century.
da Costa VG; Moreli ML; Saivish MV
Arch Virol; 2020 Jul; 165(7):1517-1526. PubMed ID: 32322993
[TBL] [Abstract][Full Text] [Related]
27. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
Akaji K; Konno H
Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
[TBL] [Abstract][Full Text] [Related]
28. COVID-19: The outbreak caused by a new coronavirus.
Sifuentes-Rodríguez E; Palacios-Reyes D
Bol Med Hosp Infant Mex; 2020; 77(2):47-53. PubMed ID: 32226003
[TBL] [Abstract][Full Text] [Related]
29. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
Ye ZW; Jin DY
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053
[TBL] [Abstract][Full Text] [Related]
30. Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2.
Körner RW; Majjouti M; Alcazar MAA; Mahabir E
Viruses; 2020 Aug; 12(8):. PubMed ID: 32806708
[TBL] [Abstract][Full Text] [Related]
31. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
Patil AM; Göthert JR; Khairnar V
Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
[TBL] [Abstract][Full Text] [Related]
32. Targeting Crucial Host Factors of SARS-CoV-2.
Tharappel AM; Samrat SK; Li Z; Li H
ACS Infect Dis; 2020 Nov; 6(11):2844-2865. PubMed ID: 33112126
[TBL] [Abstract][Full Text] [Related]
33. Molecular Basis of Pathogenesis of Coronaviruses: A Comparative Genomics Approach to Planetary Health to Prevent Zoonotic Outbreaks in the 21st Century.
Asrani P; Hasan GM; Sohal SS; Hassan MI
OMICS; 2020 Nov; 24(11):634-644. PubMed ID: 32940573
[TBL] [Abstract][Full Text] [Related]
34. A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).
Noor R
Arch Microbiol; 2021 Jul; 203(5):1943-1951. PubMed ID: 33682075
[TBL] [Abstract][Full Text] [Related]
35. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
[TBL] [Abstract][Full Text] [Related]
36. Properties of Coronavirus and SARS-CoV-2.
Malik YA
Malays J Pathol; 2020 Apr; 42(1):3-11. PubMed ID: 32342926
[TBL] [Abstract][Full Text] [Related]
37. [Coronavirus, emerging viruses].
Juckel D; Dubuisson J; Belouzard S
Med Sci (Paris); 2020; 36(6-7):633-641. PubMed ID: 32558641
[TBL] [Abstract][Full Text] [Related]
38. Drug Discovery Strategies for SARS-CoV-2.
Shyr ZA; Gorshkov K; Chen CZ; Zheng W
J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
[TBL] [Abstract][Full Text] [Related]
39. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses.
Fung SY; Yuen KS; Ye ZW; Chan CP; Jin DY
Emerg Microbes Infect; 2020; 9(1):558-570. PubMed ID: 32172672
[TBL] [Abstract][Full Text] [Related]
40. [Characteristics of SARS-CoV-2 and potential pharmacological treatment].
Pawlik L; Śpiołek E; Fichna J; Tarasiuk A
Postepy Biochem; 2020 May; 66(2):83-90. PubMed ID: 32700510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
